Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Pancreatic Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Prostatic Neoplasms 1Colonic Neoplasms 1Carcinoma 1Adenocarcinoma 1

Interventions

pembrolizumab 12Cisplatin 5Cetuximab 5Paclitaxel 4durvalumab 3Nivolumab 3Ipilimumab 3Gemcitabine 3Cyclophosphamide 3poly ICLC 2avelumab 2Radiation 2Pemetrexed 2Leucovorin 2Irinotecan 2Fluorouracil 2Carboplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vistusertib 1tislelizumab 1tirbanibulin 1spartalizumab 1sonidegib 1sitravatinib 1repotrectinib 1pralsetinib 1pertuzumab 1pepinemab 1obinutuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma × balstilimab × Clear all
NCT06782932 2025-12-03

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Recruiting
38 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡